BiotechTube

VigantOL oil plus interferon beta-1a (Rebif) + Placebo plus interferon beta-1a (Rebif) + Interferon beta-1a (Rebif®) alone

Phase 2Completed
1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Relapsing-Remitting Multiple Sclerosis

Conditions

Relapsing-Remitting Multiple Sclerosis

Trial Timeline

Feb 1, 2011 → May 1, 2015

NCT ID
NCT01285401

About VigantOL oil plus interferon beta-1a (Rebif) + Placebo plus interferon beta-1a (Rebif) + Interferon beta-1a (Rebif®) alone

VigantOL oil plus interferon beta-1a (Rebif) + Placebo plus interferon beta-1a (Rebif) + Interferon beta-1a (Rebif®) alone is a phase 2 stage product being developed by Merck for Relapsing-Remitting Multiple Sclerosis. The current trial status is completed. This product is registered under clinical trial identifier NCT01285401. Target conditions include Relapsing-Remitting Multiple Sclerosis.

What happened to similar drugs?

20 of 20 similar drugs in Relapsing-Remitting Multiple Sclerosis were approved

Approved (20) Terminated (4) Active (0)
✅Rebif® + Rebif®MerckApproved
✅Interferon beta-1a (Rebif)MerckApproved
✅Cladribine 10 mg oral tabletMerckApproved
✅Ofatumumab + Disease modifying treatment (DMT)NovartisApproved
✅fingolimodNovartisApproved
✅FingolimodNovartisApproved
✅fingolimodNovartisApproved

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01285401Phase 2Completed

Competing Products

20 competing products in Relapsing-Remitting Multiple Sclerosis

See all competitors
ProductCompanyStageHype Score
CT-P53 + US-Ocrevus + EU-OcrevusCelltrionPhase 3
47
LY2127399 + PlaceboEli LillyPhase 2
35
BIIB019 (Daclizumab High Yield Process) + PlaceboAbbViePhase 2
35
DaclizumabAbbViePhase 3
32
BIIB019 (Daclizumab High Yield Process) + PlaceboAbbViePhase 2
35
BIIB019 (Daclizumab) + trivalent seasonal influenza vaccineAbbViePhase 2
35
BIIB019 (Daclizumab)AbbViePhase 3
32
BIIB019 (Daclizumab High Yield Process) + Interferon beta-1a Placebo + Interferon beta-1a + Daclizumab High Yield Process PlaceboAbbViePhase 3
40
Rebif (Interferon beta-1a)MerckPre-clinical
26
Interferon beta-1aMerckPre-clinical
26
Rebif® + Avonex®MerckPhase 3
40
Rebif® + Rebif®MerckApproved
43
Placebo + IFN beta-1a + MethylprednisoloneMerckPhase 2
27
Interferon beta-1a (Rebif)MerckApproved
43
Evobrutinib + Avonex® + Avonex® matched Placebo + Evobrutinib matched PlaceboMerckPhase 3
32
Evobrutinib + Avonex® + Avonex® matched Placebo + Evobrutinib matched PlaceboMerckPhase 3
32
Interferon beta 1aMerckPre-clinical
26
Cladribine 10 mg oral tabletMerckApproved
39
Evobrutinib + Evobrutinib + Evobrutinib + Placebo + TecfideraMerckPhase 2
27
Minocycline + PlaceboMerckPhase 2
27